stockrow
Monday 9 November 2026
Export MGNX’s income statement to Excel — free account
MacroGenics, Inc.
MGNXMacroGenics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.5 million, roughly unchanged from fiscal 2024.
- Revenue
- +47.6%
- EPS
- +154.4%
- Free cash flow
- +12.9%
Quarter to June 2026, against a year earlier
2.33
0.11
+4.95%
Follow MGNX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.83 | 0.68 | 1.17 | 1.75 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.52) | 2.36 | (5.12) | (7.21) | |
P/B ratio |
1.59 | 1.83 | 8.65 | 6.85 | |
Price to Tangible BV |
1.59 | 1.83 | 8.65 | 6.85 | |
EV/Sales |
(0.26) | (0.55) | 0.23 | 0.76 | |
EV/EBITDA |
0.30 | 1.22 | 0.00 | 0.00 | |
EV/Operating CF |
0.21 | 1.01 | (0.51) | (1.99) | |
EV/FCF |
0.21 | 0.99 | (0.50) | (1.94) | |
Quick Ratio |
4.85 | 4.41 | 1.72 | 2.92 | |
Current Ratio |
5.22 | 5.10 | 1.90 | 2.96 | |
Net Debt/EBITDA |
(7.35) | 41.57 | 4.75 | 12.75 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.48 | 0.58 | 0.71 | 0.57 | |
Operating CF/Net income |
(1.79) | (3.04) | 0.97 | (2.09) | |
Capex/Depreciation |
(0.33) | (0.22) | (0.36) | (3.06) | |
Interest Coverage |
5.58 | (1.32) | (6.84) | (3.15) | |
Research and Development Expense of Revenue |
44.91% | 82.41% | 168.35% | 118.12% | |
Selling, General and Administrative Expense of Revenue |
13.60% | 22.40% | 46.74% | 24.07% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
4.87% | 6.45% | 12.74% | 6.01% | |
Graham Net Nets |
0.27 | 0.18 | (0.08) | 0.07 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(71.43%) | (72.67%) | (38.06%) | (4.76%) | |
Free Cash Flow Yield |
(155.09%) | (81.57%) | (39.09%) | (22.30%) | |
Revenue per Share |
1.15 | 0.65 | 0.33 | 0.52 | |
Operating CF per Share |
(0.48) | 0.68 | (0.56) | (0.64) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.48) | 0.68 | (0.57) | (0.65) | |
Cash per Share |
2.32 | 3.01 | 2.43 | 2.73 | |
Shareholders Equity per Share |
1.06 | 0.88 | 0.33 | 0.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.06 | 0.88 | 0.33 | 0.67 | |
Free Cash Flow |
(30.61) | 42.79 | (36.15) | (41.55) | |
Working Capital |
187.62 | 176.83 | 86.58 | 212.87 | |
Capital Expenditures |
(0.43) | (0.23) | (0.34) | (0.81) | |
Net Current Asset Value |
28.33 | 18.69 | (14.15) | 19.15 | |
EV/EBIT |
0.28 | 1.12 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
38.99 | 2.37 | 10.48 | 78.35 | |
Average Payables |
6.28 | 4.14 | 5.45 | 4.05 | |
Average Inventory |
4.93 | 5.58 | 9.46 | — | |
Average Assets |
267.63 | 259.25 | 221.22 | 295.41 | |
Average Common Equity |
93.53 | 85.82 | 50.16 | 44.75 |
Columns are period end dates · fundamentals updated 26 Oct 2026